CICCONE, VALERIO
 Distribuzione geografica
Continente #
EU - Europa 1.347
NA - Nord America 1.171
AS - Asia 218
AF - Africa 13
SA - Sud America 1
Totale 2.750
Nazione #
US - Stati Uniti d'America 1.170
IT - Italia 357
IE - Irlanda 283
GB - Regno Unito 235
SE - Svezia 129
RU - Federazione Russa 111
CN - Cina 71
SG - Singapore 59
VN - Vietnam 58
DE - Germania 53
FR - Francia 52
UA - Ucraina 34
FI - Finlandia 33
ES - Italia 24
IN - India 12
BE - Belgio 9
CI - Costa d'Avorio 9
TR - Turchia 9
NL - Olanda 7
AT - Austria 5
HK - Hong Kong 4
LU - Lussemburgo 4
GR - Grecia 3
TN - Tunisia 3
AZ - Azerbaigian 2
DK - Danimarca 2
KG - Kirghizistan 2
CA - Canada 1
CZ - Repubblica Ceca 1
HU - Ungheria 1
IS - Islanda 1
LK - Sri Lanka 1
LT - Lituania 1
PE - Perù 1
PL - Polonia 1
RO - Romania 1
ZA - Sudafrica 1
Totale 2.750
Città #
Dublin 279
Southend 217
Fairfield 144
Chandler 138
Ashburn 111
Santa Clara 111
Siena 92
Woodbridge 70
Wilmington 59
Dong Ket 57
Florence 56
Ann Arbor 55
Seattle 55
Cambridge 48
Singapore 45
Houston 44
Princeton 33
Jacksonville 31
Helsinki 27
Columbus 24
Málaga 23
Beijing 18
Fremont 14
Munich 14
Milan 12
Rome 11
Dearborn 10
Abidjan 9
Brussels 9
Moscow 9
Pune 9
San Mateo 9
London 8
Nanjing 8
Prato 8
San Diego 8
Boardman 7
Izmir 5
Piscataway 5
San Francisco 5
Vienna 5
Avezzano 4
Bologna 4
Cagliari 4
Castellammare di Stabia 4
Jinan 4
Luxembourg 4
New York 4
Norwalk 4
Shenyang 4
Tianjin 4
Casalnuovo di Napoli 3
Espoo 3
Falls Church 3
Fiesole 3
Kasserine 3
Marcianise 3
Naples 3
Pisa 3
Shanghai 3
Amsterdam 2
Baku 2
Berlin 2
Bishkek 2
Changsha 2
Como 2
Curinga 2
Erlangen 2
Frankfurt am Main 2
Fucecchio 2
Guangzhou 2
Gunzenhausen 2
Haikou 2
Hebei 2
Istanbul 2
Landriano 2
Massarosa 2
Nanchang 2
Ningbo 2
Peccioli 2
Phoenix 2
Recanati 2
Saint-Fons 2
Tukwila 2
Varese 2
Xánthi 2
Zhengzhou 2
Acerra 1
Acton 1
Afragola 1
Albuquerque 1
Athens 1
Atlanta 1
Bergamo 1
Bonndorf 1
Boston 1
Budapest 1
Böblingen 1
Caserta 1
Castelfranci 1
Totale 2.036
Nome #
mPGES-1 as a new target to overcome acquired resistance to gefitinib in non-small cell lung cancer cell lines 195
ALDH3A1 overexpression in melanoma and lung tumors drives cancer stem cell expansion, impairing immune surveillance through enhanced PD-L1 output 173
The metal-nonoate Ni(SalPipNONO) inhibits in vitro tumor growth, invasiveness and angiogenesis 161
Stemness marker ALDH1A1 promotes tumor angiogenesis via retinoic acid/HIF-1α/VEGF signalling in MCF-7 breast cancer cells 154
Efficacy of AdipoDren ® in Reducing Interleukin-1-Induced Lymphatic Endothelial Hyperpermeability 152
Anti-hypertensive property of a nickel-piperazine/NO donor in spontaneously hypertensive rats 142
Effect of NIR laser therapy by MLS-MiS source against neuropathic pain in rats: in vivo and ex vivo analysis 137
Comparison of the Effect of Two Hyaluronic Acid Preparations on Fibroblast and Endothelial Cell Functions Related to Angiogenesis 129
By-products from winemaking and olive mill value chains for the enrichment of refined olive oil: Technological challenges and nutraceutical features 118
Endothelium as therapeutic target in breast and lung cancer progression: the role of nitric oxide and stemness marker ALDH1A1 116
Molecular mechanisms of resistance to anti-angiogenic drugs 103
Characterization of the Safety Profile of Sweet Chestnut Wood Distillate Employed in Agriculture 97
Effect of nir laser therapy by mls‐mis source on fibroblast activation by inflammatory cytokines in relation to wound healing 93
Development of fortified citrus olive oils: From their production to their nutraceutical properties on the cardiovascular system 90
Endothelium as a source and target of H2S to improve its trophism and function 90
Pharmacological Inhibition of CA-IX Impairs Tumor Cell Proliferation, Migration and Invasiveness 86
Studying Angiogenesis in the Rabbit Corneal Pocket Assay 85
Chapter 2. Antiangiogenic drugs: Chemosensitizers for combination cancer therapy 79
ALDH1A1 overexpression in melanoma cells promotes tumor angiogenesis by activating the IL‑8/Notch signaling cascade 75
Scoping Review on Platelets and Tumor Angiogenesis: Do We Need More Evidence or Better Analysis? 58
The H2S-donor erucin exhibits protective effects against vascular inflammation in human endothelial and smooth muscle cells 58
How to conjugate the stemness marker ALDH1A1 with tumor angiogenesis, progression, and drug resistance 57
State-of-the-Art in Antiangiogenic Agents in Cancer Therapy 56
Anti-Inflammatory Effect of the Natural H2S-Donor Erucin in Vascular Endothelium 54
ALDH1A1 confers resistance to RAF/MEK inhibitors in melanoma cells by maintaining stemness phenotype and activating PI3K/AKT signaling 52
Promising Support Coming from Nature: Antioxidant and Anti-Inflammatory Potential of Castanea sativa Wood Distillate on Skin Cells 50
Optimization of an Ex-Vivo Human Skin/Vein Model for Long-Term Wound Healing Studies: Ground Preparatory Activities for the 'Suture in Space' Experiment Onboard the International Space Station 50
Safety of Anti-Angiogenic Drugs in Pediatric Patients with Solid Tumors: A Systematic Review and Meta-Analysis 45
The Nitric Oxide Donor [Zn(PipNONO)Cl] Exhibits Antitumor Activity through Inhibition of Epithelial and Endothelial Mesenchymal Transitions 35
Erucin, a natural isothiocyanate, exerts pro-angiogenic properties in cultured endothelial cells and reverts angiogenic impairment induced by high glucose 30
Cornerstones of CT urography: a shared document by the Italian board of urogenital radiology 29
ERK5 mediates pro-tumorigenic phenotype in non-small lung cancer cells induced by PGE2 22
null 5
Preclinical models to assess the pharmacological properties of NO derivatives 2
Totale 2.878
Categoria #
all - tutte 12.515
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.515


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020204 0 0 0 0 0 0 37 46 39 33 26 23
2020/2021481 18 28 11 34 53 53 10 51 39 69 27 88
2021/2022405 26 32 31 43 52 21 14 24 16 24 51 71
2022/2023523 28 64 57 55 42 117 23 38 51 27 15 6
2023/2024450 13 10 44 38 17 120 155 11 5 7 8 22
2024/2025541 40 68 109 124 112 79 9 0 0 0 0 0
Totale 2.878